Bullfrog AI Holdings, Inc. Common Stock (BFRG)
US — Healthcare Sector
Automate Your Wheel Strategy on BFRG
With Tiblio's Option Bot, you can configure your own wheel strategy including BFRG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BFRG
- Rev/Share 0.0002
- Book/Share 0.335
- PB 4.9099
- Debt/Equity 0.0
- CurrentRatio 4.8631
- ROIC -2.257
- MktCap 15488539.0
- FreeCF/Share -0.5683
- PFCF -2.8127
- PE -2.2427
- Debt/Assets 0.0
- DivYield 0
- ROE -1.6322
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
About Bullfrog AI Holdings, Inc. Common Stock (BFRG)
- IPO Date 2023-02-13
- Website https://www.bullfrogai.com
- Industry Medical - Healthcare Information Services
- CEO Mr. Vininder Singh
- Employees 4
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.